Using the well-established Self Esteem and Relationship (SEAR) questionnaire, it was determined that at week 24, 85.4% of MED3000 users felt that sex could be spontaneous (Includes: Always/Almost ...
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on ...
European Patent Office grants patent for MED3000 providing protection to 2040 Futura Medical plc (AIM: FUM), the pharmaceutical company developing innovative sexual health products, today announces ...
Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on ...
- Company also announced that it raised proceeds of £4,375,000 to fund future commercialization of MED3000 via a warrant exercise by a large institutional shareholder - GUILDFORD, England, June 12, ...
Futura Medical has reported phase 3 data on its topical erectile dysfunction treatment MED3000, teeing it up to file for FDA approval of the therapy as an over-the-counter medicine by the end of the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In a confirmatory study, MED3000 was associated with ...
The FDA has granted over-the-counter marketing authorization to MED3000 (Eroxon), the first nonprescription topical gel for treating erectile dysfunction (ED) in men age 22 and older, maker Futura ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results